Table 3.
Toxicities, adverse events, and malignancy relapse
| Toxicities and adverse events | N = 26/79 (32.9%) |
|---|---|
| Infections | 4 (5) |
| Fungal infection | 2 |
| Bacterial/viral infection | 2 |
| Cytopenia | 14 (17.7) |
| Anemia | 3 |
| Leukopenia | 2 |
| Thrombocytopenia | 5 |
| Combinations | 4 |
| Others | 8 (10.1) |
| Renal impairment | 3 |
| Hepatic impairment | 3 |
| Hypertension | 1 |
| Edema | 1 |
| Action | |
| Dose reduction | 14 (17.7) |
| Temporary suspension | 2 (2.5) |
| Discontinuation | 3 (3.7) |
| No actions/Others | 7 (8.8) |
| Malignancy relapse | 1 (1.2) |